[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 632,284,928
  • Shares Outstanding, K 2,409,898
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,453 M
  • EBITDA $ 30,956 M
  • 60-Month Beta 0.24
  • Price/Sales 6.66
  • Price/Cash Flow 18.44
  • Price/Book 7.38

Options Overview Details

View History
  • Implied Volatility 22.23% (-0.39%)
  • Historical Volatility 22.70%
  • IV Percentile 55%
  • IV Rank 47.79%
  • IV High 30.74% on 07/07/26
  • IV Low 14.44% on 08/19/25
  • Expected Move (DTE 2) 4.34 (1.60%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 52,976
  • Volume Avg (30-Day) 30,137
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 400,314
  • Open Int (30-Day) 381,459
  • Expected Range 266.77 to 275.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.95
  • Number of Estimates 6
  • High Estimate $3.14
  • Low Estimate $2.49
  • Prior Year $2.80
  • Growth Rate Est. (year over year) +5.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
245.49 +10.44%
on 07/21/26
274.90 -1.38%
on 07/28/26
+18.07 (+7.14%)
since 07/17/26
3-Month
220.84 +22.76%
on 06/01/26
274.90 -1.38%
on 07/28/26
+42.19 (+18.43%)
since 05/18/26
52-Week
173.33 +56.41%
on 09/19/25
274.90 -1.38%
on 07/28/26
+94.86 (+53.82%)
since 08/18/25

Most Recent Stories

More News
These 3 Low- and Min-Vol ETFs Fend Off Market Jitters

High-volatility environments can spell danger for stocks. These funds cobble together lower-volatility portfolios to protect against market downside.

SPLV : 76.03 (+0.38%)
VFMV : 146.06 (+0.16%)
SMLV : 160.04 (-0.44%)
KO : 88.82 (+2.12%)
JNJ : 271.11 (+3.33%)
DUK : 123.99 (+0.33%)
FE : 47.26 (-0.34%)
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern...

JNJ : 271.11 (+3.33%)
5 Stocks the Market Rewarded After Strong Earnings Results

Amazon, Microsoft, JPMorgan Chase, Johnson & Johnson and Coca-Cola posted strong earnings beats that held up, with cloud growth, capital returns and raised guidance fueling sustained stock gains.

MSFT : 481.63 (+0.27%)
KO : 88.82 (+2.12%)
JPM : 363.25 (+0.63%)
JNJ : 271.11 (+3.33%)
AMZN : 259.45 (-0.71%)
Build Dividend Income at Low Cost With These ETFs

VYM, VCIT, and AGG offer low-cost ETF options for income investors, combining dividend yields between 2.20% and 4.86% with broad diversification and expense ratios as low as 0.03%.

VCIT : 81.07 (+0.06%)
AGG : 97.35 (+0.10%)
JNJ : 271.11 (+3.33%)
PG : 143.45 (+0.23%)
VYM : 165.55 (-0.08%)
Solventum Nears Inflection Point As It Begins to Unlock Value

Solventum shares gain on strong Q2 revenue, earnings, and cash flow, buybacks, and improved guidance, with analysts raising price targets amid a discounted valuation versus med/tech peers.

SOLV : 87.45 (+0.73%)
ABT : 112.68 (+2.09%)
JNJ : 271.11 (+3.33%)
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9 th , 2026. Management will participate in a Fireside Chat at 11:00 a.m....

JNJ : 271.11 (+3.33%)
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and...

JNJ : 271.11 (+3.33%)
The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

JPM : 363.25 (+0.63%)
XOM : 165.56 (+2.54%)
JNJ : 271.11 (+3.33%)
SCHV : 35.08 (-0.68%)
MU : 940.76 (-7.02%)
BRK-B : N/A (N/A)
ABBV : 258.92 (+3.43%)
WMT : 115.20 (+0.76%)
Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

Johnson & Johnson has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

XLV : 169.73 (+1.60%)
$SPX : 7,691.76 (-0.69%)
JNJ : 271.11 (+3.33%)
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address...

JNJ : 271.11 (+3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 278.52
2nd Resistance Point 275.12
1st Resistance Point 273.12
Last Price 271.11
1st Support Level 267.72
2nd Support Level 264.32
3rd Support Level 262.32

See More

52-Week High 274.90
Last Price 271.11
Fibonacci 61.8% 236.10
Fibonacci 50% 224.11
Fibonacci 38.2% 212.13
52-Week Low 173.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.